PubMed:32222463 / 0-268 JSONTXT

{"project":"LitCovid-OGER-BB","denotations":[{"id":"T1","span":{"begin":0,"end":9},"obj":"DG_29"},{"id":"T2","span":{"begin":11,"end":21},"obj":"DG_28"},{"id":"T3","span":{"begin":23,"end":33},"obj":"DG_33"},{"id":"T4","span":{"begin":35,"end":46},"obj":"DG_19"},{"id":"T5","span":{"begin":35,"end":46},"obj":"NCBITaxon:61463"},{"id":"T6","span":{"begin":52,"end":61},"obj":"NCBITaxon:192387"},{"id":"T7","span":{"begin":70,"end":80},"obj":"SP_7"},{"id":"T8","span":{"begin":157,"end":162},"obj":"SP_6"},{"id":"T9","span":{"begin":157,"end":162},"obj":"NCBITaxon:9606"},{"id":"T10","span":{"begin":163,"end":174},"obj":"NCBITaxon:11118"},{"id":"T11","span":{"begin":209,"end":219},"obj":"SP_7"}],"namespaces":[{"prefix":"NCBITaxon","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"}],"text":"Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study.\nAIMS: A new human coronavirus (HCoV), which has been designated SARS-CoV-2, began spreading in December 2019 in Wuhan City,"}

{"project":"LitCovid-sentences-v1","denotations":[{"id":"TextSentencer_T1","span":{"begin":0,"end":117},"obj":"Sentence"},{"id":"TextSentencer_T2","span":{"begin":118,"end":144},"obj":"Sentence"},{"id":"TextSentencer_T3","span":{"begin":145,"end":150},"obj":"Sentence"}],"text":"Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study.\nAIMS: A new human coronavirus (HCoV), which has been designated SARS-CoV-2, began spreading in December 2019 in Wuhan City,"}

{"project":"LitCovid-TimeML","denotations":[{"id":"tok1","span":{"begin":0,"end":9},"obj":"NNP"},{"id":"tok2","span":{"begin":9,"end":10},"obj":","},{"id":"tok3","span":{"begin":11,"end":21},"obj":"NNP"},{"id":"tok4","span":{"begin":21,"end":22},"obj":","},{"id":"tok5","span":{"begin":23,"end":33},"obj":"NNP"},{"id":"tok6","span":{"begin":33,"end":34},"obj":","},{"id":"tok7","span":{"begin":35,"end":46},"obj":"NNP"},{"id":"tok8","span":{"begin":46,"end":47},"obj":","},{"id":"tok9","span":{"begin":48,"end":51},"obj":"CC"},{"id":"tok10","span":{"begin":52,"end":61},"obj":"NNP"},{"id":"tok11","span":{"begin":62,"end":69},"obj":"IN"},{"id":"tok12","span":{"begin":70,"end":79},"obj":"NNP"},{"id":"tok13","span":{"begin":79,"end":80},"obj":"CD"},{"id":"tok14","span":{"begin":81,"end":84},"obj":"NNP"},{"id":"tok15","span":{"begin":85,"end":94},"obj":"JJ"},{"id":"tok16","span":{"begin":95,"end":98},"obj":"NNP"},{"id":"tok17","span":{"begin":99,"end":109},"obj":"NN"},{"id":"tok18","span":{"begin":110,"end":111},"obj":"("},{"id":"tok19","span":{"begin":111,"end":115},"obj":"NNP"},{"id":"tok20","span":{"begin":115,"end":116},"obj":")"},{"id":"tok21","span":{"begin":116,"end":117},"obj":":"},{"id":"tok22","span":{"begin":118,"end":119},"obj":"DT"},{"id":"tok23","span":{"begin":120,"end":129},"obj":"JJ"},{"id":"tok24","span":{"begin":130,"end":137},"obj":"VBG"},{"id":"tok25","span":{"begin":138,"end":143},"obj":"NN"},{"id":"tok26","span":{"begin":143,"end":144},"obj":"."},{"id":"tok27","span":{"begin":145,"end":149},"obj":"NNP"},{"id":"tok28","span":{"begin":149,"end":150},"obj":":"},{"id":"tok29","span":{"begin":151,"end":152},"obj":"DT"},{"id":"tok30","span":{"begin":153,"end":156},"obj":"JJ"},{"id":"tok31","span":{"begin":157,"end":162},"obj":"JJ"},{"id":"tok32","span":{"begin":163,"end":174},"obj":"JJ"},{"id":"tok33","span":{"begin":175,"end":176},"obj":"("},{"id":"tok34","span":{"begin":176,"end":180},"obj":"NNP"},{"id":"tok35","span":{"begin":180,"end":181},"obj":")"},{"id":"tok36","span":{"begin":181,"end":182},"obj":","},{"id":"tok37","span":{"begin":183,"end":188},"obj":"WDT"},{"id":"tok38","span":{"begin":189,"end":192},"obj":"VBZ"},{"id":"tok39","span":{"begin":193,"end":197},"obj":"VBN"},{"id":"tok40","span":{"begin":198,"end":208},"obj":"VBN"},{"id":"tok41","span":{"begin":209,"end":218},"obj":"NNP"},{"id":"tok42","span":{"begin":218,"end":219},"obj":"CD"},{"id":"tok43","span":{"begin":219,"end":220},"obj":","},{"id":"tok44","span":{"begin":221,"end":226},"obj":"VBD"},{"id":"tok45","span":{"begin":227,"end":236},"obj":"VBG"},{"id":"tok46","span":{"begin":237,"end":239},"obj":"IN"},{"id":"tok47","span":{"begin":240,"end":248},"obj":"NNP"},{"id":"tok48","span":{"begin":249,"end":253},"obj":"CD"},{"id":"tok49","span":{"begin":254,"end":256},"obj":"IN"},{"id":"tok50","span":{"begin":257,"end":262},"obj":"NNP"},{"id":"tok51","span":{"begin":263,"end":267},"obj":"NNP"},{"id":"tok52","span":{"begin":267,"end":268},"obj":","},{"id":"lookup1","span":{"begin":237,"end":239},"obj":"country_code"},{"id":"lookup2","span":{"begin":240,"end":248},"obj":"date"},{"id":"lookup3","span":{"begin":249,"end":253},"obj":"year"},{"id":"lookup4","span":{"begin":254,"end":256},"obj":"country_code"},{"id":"lookup5","span":{"begin":257,"end":262},"obj":"location"},{"id":"lookup6","span":{"begin":263,"end":267},"obj":"location"},{"id":"lookup7","span":{"begin":263,"end":267},"obj":"loc_key"},{"id":"event2","span":{"begin":198,"end":208},"obj":"OCCURRENCE"},{"id":"event10","span":{"begin":221,"end":226},"obj":"ASPECTUAL"},{"id":"event17","span":{"begin":227,"end":236},"obj":"OCCURRENCE"}],"text":"Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study.\nAIMS: A new human coronavirus (HCoV), which has been designated SARS-CoV-2, began spreading in December 2019 in Wuhan City,"}

{"project":"LitCovid-PD-MONDO-v1","denotations":[{"id":"T1","span":{"begin":70,"end":78},"obj":"Disease"},{"id":"T2","span":{"begin":70,"end":74},"obj":"Disease"},{"id":"T3","span":{"begin":209,"end":217},"obj":"Disease"},{"id":"T4","span":{"begin":209,"end":213},"obj":"Disease"}],"attributes":[{"id":"A1","pred":"mondo_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A2","pred":"mondo_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A3","pred":"mondo_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A4","pred":"mondo_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study.\nAIMS: A new human coronavirus (HCoV), which has been designated SARS-CoV-2, began spreading in December 2019 in Wuhan City,"}

{"project":"LitCovid-PD-FMA-UBERON-v1","denotations":[{"id":"T1","span":{"begin":81,"end":84},"obj":"Body_part"},{"id":"T2","span":{"begin":95,"end":98},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"fma_id","subj":"T1","obj":"http://purl.org/sig/ont/fma/fma67095"},{"id":"A2","pred":"fma_id","subj":"T2","obj":"http://purl.org/sig/ont/fma/fma67095"}],"text":"Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study.\nAIMS: A new human coronavirus (HCoV), which has been designated SARS-CoV-2, began spreading in December 2019 in Wuhan City,"}